Lineage Cell Therapeutics (LCTX) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Lineage Cell Therapeutics (LCTX) over the past year, gaining 75.5% versus a loss of 45.2%. Over five years, SLGL leads with a -22.8% price change compared with -59.7% for LCTX. Lineage Cell Therapeutics is the larger company by market cap ($239.7 million vs $235.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LCTX | SLGL |
|---|---|---|
| Share price | $0.9476 | $71.95 |
| Market cap | $239.66M | $235.55M |
| 1-day change | +1.03% | -4.88% |
| YTD return | -43.26% | +70.73% |
| 1-year return | -45.23% | +75.52% |
| 5-year return | -59.68% | -22.85% |
| EPS (TTM) | $-0.19 | $-5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.09 | $97.97 |
| 52-week low | $0.88 | $28.81 |
| Distance from 52-week high | -54.66% | -26.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +480.41% | +111.97% |
| Average volume | 1.15M | 55.68K |
| Shares outstanding | 252.91M | 3.27M |
| Employees | 72 | 28 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed LCTX by 120.7 percentage points over the past year.
About Lineage Cell Therapeutics
LCTX stock →Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries.
Healthcare · Biotechnology · 72 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Healthcare · Biotechnology · 28 employees
LCTX vs SLGL FAQ
Which is bigger, Lineage Cell Therapeutics or Sol-Gel Technologies?
Lineage Cell Therapeutics (LCTX) is larger, with a market capitalization of $239.66M compared with $235.55M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, LCTX or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -45.23% for LCTX (price return, excluding dividends). Past performance does not predict future results.
Are Lineage Cell Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.